DexCom, Inc.  DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong first-quarter 2026 performance and a robust international foothold are expected to contribute further.

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

DexCom faces a pivotal transition as GLP-1 adoption threatens its core insulin-treated diabetes market. DXCM aims to expand CGM adoption to Type 2 non-insulin patients, but commercial uptake remains unproven despite positive clinical trial results. At 28x earnings, DXCM's valuation is not demanding, yet offers limited upside given execution risks and the need for evidence of new market penetration.

DXCM outpaces Abbott with expanding CGM access, new product launches and broader coverage, making it the stronger stock to watch now.

DXCM's redesigned Stelo app is set for a July U.S. rollout, with international expansion and pediatric clearance broadening its glucose insights push.

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced at Aspen Ideas: Health a series of milestones that advance its vision of making glucose biosensing more accessible. Notably, the company announced pediatric clearance for the Stelo Glucose Biosensor and the launch of its fully reimagined Stelo app experience in July for Apple iPhone and Android users in the United States.“Glucose matters for everyone and better understanding it can h.

The GLP-1 revolution is quietly continuing even as investor interest has moved on to more timely topics. One of the best ways to access the fast-growing weight loss drug space is via makers like Novo Nordisk NYSE: NVO or Eli Lilly NYSE: LLY, the leading companies responsible for developing and manufacturing products like Ozempic and Zepbound.

TD Cowen analysts estimate that the total addressable market for longevity healthcare exceeds $250 billion.

Until recently, it had been a lackluster year for the healthcare sector. From high medical utilization squeezing insurers to structural cost pressures and valuation hangovers, medical stocks stocks have lagged much of the broader market this year.

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.